Amanote Research
Register
Sign In
Discover open access scientific publications
Search, annotate, share and cite publications
Publications by Jesse Peterson-Brandt
Real-World Cost of Treatment for Multiple Sclerosis Patients Initiating and Receiving Infused Disease-Modifying Therapies Per Recommended Label in the United States
Journal of Medical Economics
Health Policy
Related publications
PND61 Impact of Patient Cost-Sharing Arrangements for Disease Modifying Therapies on Treatment Compliance Among Patients With Multiple Sclerosis in the United States
Value in Health
Medicine
Health Policy
Public Health
Occupational Health
Environmental
Real-World Treatment Patterns Among Patients Initiating Small Molecule Kinase Inhibitor Therapies for Thyroid Cancer in the United States
Advances in Therapy
Medicine
Pharmacology
Hypogammaglobulinemia in Multiple Sclerosis Patients Receiving Disease-Modifying Immunomodulatory Agents
Journal of Allergy and Clinical Immunology
Allergy
Immunology
Disease-Modifying Therapies in Relapsing–remitting Multiple Sclerosis
Neuropsychiatric Disease and Treatment
Psychiatry
Mental Health
Biological Psychiatry
Real World Treatment Patterns of Patients With Ovarian Cancer Receiving First Line Chemotherapy in the United States
Value in Health
Medicine
Health Policy
Public Health
Occupational Health
Environmental
Price Analysis of Multiple Sclerosis Disease-Modifying Therapies Marketed in the US
Value in Health
Medicine
Health Policy
Public Health
Occupational Health
Environmental
Pnd55 - A Cost-Effectiveness Analysis Using Real-World Data From the Msbase Registry: Comparing Natalizumab to Fingolimod in Patients With Inadequate Response to Disease-Modifying Therapies in Relapsing-Remitting Multiple Sclerosis in Italy
Value in Health
Medicine
Health Policy
Public Health
Occupational Health
Environmental
Pnd56 - A Cost-Effectiveness Analysis Using Real-World Data From the Msbase Registry: Comparing Natalizumab to Fingolimod in Patients With Inadequate Response to Disease-Modifying Therapies in Relapsing-Remitting Multiple Sclerosis in Spain
Value in Health
Medicine
Health Policy
Public Health
Occupational Health
Environmental
Cost-Effectiveness of Alemtuzumab in the Treatment of Relapsing Forms of Multiple Sclerosis in the United States
Value in Health
Medicine
Health Policy
Public Health
Occupational Health
Environmental
